Zydus Lifesciences Unit Buys 5.9% Stake in Agenus for $16 Million

MT Newswires Live

Jun 04

Zydus Lifesciences Ltd (BOM:532321, NSE:ZYDUSLIFE) wholly owned subsidiary, Zynext Ventures USA LLC, acquired a 5.9% stake in US-based immuno-oncology company Agenus Inc, according to a Tuesday filing on the local bourse.

The purchase of 2.13 million shares cost approximately $16 million at $7.50 per share.

Agenus develops next-generation immunotherapies, including Botensilimab and Balstilimab, which are in advanced clinical trials for multiple cancer types. The investment aims to accelerate these programmes and expand their application in earlier treatment stages.

The deal is subject to regulatory approvals, including those under US antitrust and foreign investment laws. Zynext Ventures plans to complete the acquisition within 60 days, with a possible 30-day extension.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2540882820"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540882820\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2540882820?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-04 07:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540882820","market":"sh","top_or_hot":-1,"title":"Zydus Lifesciences Unit Buys 5.9% Stake in Agenus for $16 Million","media":"MT Newswires Live","content":"<html><body><p> Zydus Lifesciences Ltd (BOM:532321, NSE:ZYDUSLIFE) wholly owned subsidiary, Zynext Ventures USA LLC, acquired a 5.9% stake in US-based immuno-oncology company Agenus Inc, according to a Tuesday filing on the local bourse.</p><p>The purchase of 2.13 million shares cost approximately $16 million at $7.50 per share.</p><p>Agenus develops next-generation immunotherapies, including Botensilimab and Balstilimab, which are in advanced clinical trials for multiple cancer types. The investment aims to accelerate these programmes and expand their application in earlier treatment stages.</p><p>The deal is subject to regulatory approvals, including those under US antitrust and foreign investment laws. Zynext Ventures plans to complete the acquisition within 60 days, with a possible 30-day extension.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zydus Lifesciences Unit Buys 5.9% Stake in Agenus for $16 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZydus Lifesciences Unit Buys 5.9% Stake in Agenus for $16 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-06-04 07:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Zydus Lifesciences Ltd (BOM:532321, NSE:ZYDUSLIFE) wholly owned subsidiary, Zynext Ventures USA LLC, acquired a 5.9% stake in US-based immuno-oncology company Agenus Inc, according to a Tuesday filing on the local bourse.</p><p>The purchase of 2.13 million shares cost approximately $16 million at $7.50 per share.</p><p>Agenus develops next-generation immunotherapies, including Botensilimab and Balstilimab, which are in advanced clinical trials for multiple cancer types. The investment aims to accelerate these programmes and expand their application in earlier treatment stages.</p><p>The deal is subject to regulatory approvals, including those under US antitrust and foreign investment laws. Zynext Ventures plans to complete the acquisition within 60 days, with a possible 30-day extension.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2540882820","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540882820","pubTimestamp":1748992743,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Zydus Lifesciences Ltd  wholly owned subsidiary, Zynext Ventures USA LLC, acquired a 5.9% stake in US-based immuno-oncology company Agenus Inc, according to a Tuesday filing on the local bourse.The purchase of 2.13 million shares cost approximately $16 million at $7.50 per share.Agenus develops next-generation immunotherapies, including Botensilimab and Balstilimab, which are in advanced clinical trials for multiple cancer types. The investment aims to accelerate these programmes and expand their application in earlier treatment stages.The deal is subject to regulatory approvals, including those under US antitrust and foreign investment laws. Zynext Ventures plans to complete the acquisition within 60 days, with a possible 30-day extension.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","AGEN":"艾吉纳斯公司"},"translate_title":"Zydus Lifesciences部门以1600万美元收购Agenus 5.9%的股份","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AGEN":1},"content_text":"Zydus Lifesciences Ltd (BOM:532321, NSE:ZYDUSLIFE) wholly owned subsidiary, Zynext Ventures USA LLC, acquired a 5.9% stake in US-based immuno-oncology company Agenus Inc, according to a Tuesday filing on the local bourse.The purchase of 2.13 million shares cost approximately $16 million at $7.50 per share.Agenus develops next-generation immunotherapies, including Botensilimab and Balstilimab, which are in advanced clinical trials for multiple cancer types. The investment aims to accelerate these programmes and expand their application in earlier treatment stages.The deal is subject to regulatory approvals, including those under US antitrust and foreign investment laws. Zynext Ventures plans to complete the acquisition within 60 days, with a possible 30-day extension.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}